West Pharmaceutical Services (WST) just posted its FY 2025 third quarter scorecard, with revenue of US$804.6 million and basic EPS of US$1.94 setting the tone for the latest update. The company has seen revenue move from US$702.1 million in Q2 2024 to US$804.6 million in Q3 2025, while basic EPS has ranged from US$1.52 in Q2 2024 to US$1.94 in the latest quarter. This gives investors a clearer view of how the top line and per share earnings have tracked through the last six reported periods as they weigh the outlook for margins and potential future growth drivers.

See our full analysis for West Pharmaceutical Services.

With the headline numbers on the table, the next step is to see how this earnings print lines up with the widely followed narratives about West Pharmaceutical Services, highlighting where the data supports the story and where it challenges it.

Margins Slip From 17.4% To 16.3%

• The trailing net profit margin is 16.3%, compared with 17.4% a year earlier, alongside trailing twelve month net income of US$491.7 million on US$3.0b of revenue.
• Analysts' consensus view expects margins to improve over time. However, the current 16.3% margin and the move down from 17.4% highlight a tension:
  • Consensus points to profit margins rising to 18.9% in three years, while the latest trailing figures sit below that starting point.
  • LT earnings have declined 1.6% per year over five years, so the margin drift adds another data point that cautious investors will pay attention to.

6% Revenue Growth Vs Market 10.4%

• Over the last 12 months, revenue growth of about 6% per year trails the 10.4% rate cited for the broader US market, even as Q3 FY 2025 revenue stands at US$804.6 million.
• Analysts' consensus narrative focuses on potential for future revenue, and the latest mix comments help explain both the opportunities and the risks:
  • Consensus highlights GLP 1 and high value product components, which made up about 7% of revenue in an earlier quarter and are tied to roughly 340 Annex 1 projects, as key drivers for higher growth.
  • At the same time, consensus flags demand shifts, destocking in Biologics HVP components and tariff pressures as factors that could keep actual growth closer to the recent 6% trend than the 6.5% annual revenue outlook.

P/E Premium And DCF Gap

• The shares trade at US$243.61 with a P/E of 35.6x, compared with a peer average of 21.3x, the North American Life Sciences industry at 33.4x and a DCF fair value of US$54.99.
• More optimistic views focus on earnings prospects, while more cautious investors point to valuation, and the data clearly feeds both sides:
  • Forecasts call for earnings to grow about 12.4% per year, and consensus targets imply upside from US$243.61 to around US$333.57 if those forecasts materialize.
  • Critics highlight that the current P/E is above peers and the industry while trailing earnings have declined 1.6% per year over five years, and the share price sits well above the DCF fair value, so expectations are already built into the price.

On a valuation story like this, it can be useful to see how more optimistic and more cautious analysts are framing the same numbers side by side, especially around that P/E premium and the DCF gap, so you can decide which parts of the story you agree with most. 📊 Read the full West Pharmaceutical Services Consensus Narrative.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for West Pharmaceutical Services on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

See the numbers differently? Take a couple of minutes to test your own view against the figures and turn that into a clear narrative of your own, Do it your way.

A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding West Pharmaceutical Services.

See What Else Is Out There

West Pharmaceutical Services is contending with softer margins, modest 6% revenue growth versus the broader market, and a rich 35.6x P/E that sits well above its DCF fair value.

If that mix of slower growth and a valuation gap worries you, shift your focus toward companies trading closer to their fundamentals using our 55 high quality undervalued stocks today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.